Posted in | News | Discoveries

Canada Fluorspar Reports Assay Results from Director Vein Structure

Canada Fluorspar, a specialty mineral resource company, declared that it has made a significant progress on its trenching program, which is being conducted along the Director Vein’s southern extension. High grade fluorspar mineralization has been demonstrated by current assays.

Assay results have been obtained for samples taken from Trench #4 and #5 along the trace of the Director Vein structure, which is sub-vertical and extends towards north-northwest direction. The trenches #4 and #5 are spaced 100 m apart and located 100 m and 200 m south of Trench #3, respectively. Mining at the two sites revealed considerable fluorspar mineralization in Trench #4 and expanded the Director Vein structure to 750 m along strike.

Trench #4 contains 33.3% CaF2 over 3.1 m of gouge and 81.3% CaF2 over 2.9 m of CaF2; the collective grade over 6.0 m is 56.49% CaF2. Trench #5 includes fault gouge with a grade of 2.66% CaF2 over a thickness of 7.2 m. Through the trenching program, the company has discovered the southern extension of the Director Vein structure in a region, which remained untested till date. Diamond drilling is needed to assess the resource potential of the structure. Assays from these and other trenches taken during the 2012 trench sampling campaign are conducted at SGS Minerals laboratory in Lakefield, Ontario. Ion Selective Electrode method and Dual Calcium method are used to evaluate the fluorspar content in low-grade and high-grade samples, respectively. SGS handles the internal check assay work, while staff at Canada Fluorspar review and confirm the assay results.

Material results of the Director Vein reconnaissance campaign, including preliminary exploration data on these trenches, have been already announced. Assay results from samples taken from the mineralized structure are still pending.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Canada Fluorspar Inc.. (2019, February 18). Canada Fluorspar Reports Assay Results from Director Vein Structure. AZoMining. Retrieved on November 23, 2024 from https://www.azomining.com/News.aspx?newsID=6284.

  • MLA

    Canada Fluorspar Inc.. "Canada Fluorspar Reports Assay Results from Director Vein Structure". AZoMining. 23 November 2024. <https://www.azomining.com/News.aspx?newsID=6284>.

  • Chicago

    Canada Fluorspar Inc.. "Canada Fluorspar Reports Assay Results from Director Vein Structure". AZoMining. https://www.azomining.com/News.aspx?newsID=6284. (accessed November 23, 2024).

  • Harvard

    Canada Fluorspar Inc.. 2019. Canada Fluorspar Reports Assay Results from Director Vein Structure. AZoMining, viewed 23 November 2024, https://www.azomining.com/News.aspx?newsID=6284.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.